An edible mushroom sold as powder, capsule or extract, marketed chiefly for memory and mood. Older adults whose memory was already slipping scored better on standard bedside memory tests while taking it, with the gain fading after stopping. People with low mood, anxiety or poor sleep found those complaints eased. In adults without complaints, results are mixed and mostly negative. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–26 U/L (women), 10–33 U/L (men) | Detects the liver-enzyme rise seen in the one published case |
| AST | 10–26 U/L | Confirms whether a liver-enzyme rise is hepatic rather than muscular |
| Eosinophil count | Under 3% of white cells (below 0.3 ×10⁹/L) | Flags an allergic response before rash or wheeze appears |
| Fasting glucose | 75–86 mg/dL (4.2–4.8 mmol/L) | Detects additive glucose lowering in people on diabetes medication |
| HbA1c | 5.0–5.4% | Shows whether a glucose change is sustained or incidental |
| hs-CRP | Below 1.0 mg/L | Tracks the anti-inflammatory claim, which is unproven in humans |
| Validated cognitive score, e.g. MMSE | No established target; change from the individual's own baseline, with a 1–2 point rise matching the trial effect | The only endpoint the positive trials actually moved |
Cadence: Baseline before the first dose; liver panel and complete blood count repeated at 12 weeks, then every 6–12 months while use continues. Cognitive or mood instrument at 8 and 16 weeks, then every 6 months. Closer monitoring during the first month for people on glucose-lowering or antiplatelet medication.